Moxetumomab Pasudotox: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Moxetumomab Pasudotox. Educational only — not medical advice.
Labeled uses
LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
Source: FDA labeling via NIH DailyMed (set 8ddffb08…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.